Humoral response to hepatitis B vaccination and its relationship with T CD45RA+ (naïve) and CD45RO+ (memory) subsets in HIV-1-infected subjects

• Published in: Vaccine 2006-11, Vol.24 (49), p.7124-7128
• Main Authors: Veiga, Ana Paula Rocha, Casseb, Jorge, Duarte, Alberto J.S.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Antibody Formation - immunology; Antiretroviral drugs; Antiretroviral Therapy, Highly Active; Applied microbiology; Biological and medical sciences; Blotting, Western; CD4 Lymphocyte Count; Drug therapy; Enzyme-Linked Immunosorbent Assay; Female; Fundamental and applied biological sciences. Psychology; HBV; Hepatitis; Hepatitis B - immunology; Hepatitis B Vaccines - immunology; Hepatitis B virus; HIV; HIV Antibodies - analysis; HIV Antibodies - biosynthesis; HIV Infections - drug therapy; HIV Infections - immunology; HIV-1; Human immunodeficiency virus; Human viral diseases; Humans; Immune response; Immunologic Memory - immunology; Infectious diseases; Leukocyte Common Antigens - immunology; Longitudinal Studies; Lymphocytes; Male; Medical sciences; Microbiology; Middle Aged; Miscellaneous; Predictive Value of Tests; Public health; RNA, Viral - blood; T-Lymphocyte Subsets - immunology; Vaccine; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Viral diseases; Viral hepatitis; Viral Load; Virology; Virus Replication - drug effects
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2006.06.079

HIV disease leads to defects in cell-mediated immunity, impairing the immune response to new and recall antigens. We studied 55 HIV 1-infected patients who received of recombinant DNA hepatitis B vaccine and 20 controls. The overall hepatitis B virus (HBV) seroconversion rate was 59%. The median CD4+ T cell count among responders was 452 cell/mm 3, higher than non-responders (359 cells/mm 3). The HIV plasmaviral loads were higher in non-responders. We concluded that total T CD4 cell count, memory T CD4+ cells and lower plasma viral load among HIV-1-infected subjects treated with HAART could be used to predict the immune response to vaccination with hepatitis B vaccine. Thus, considering cost benefits, HVB vaccination should be preferentially provided to HIV-infected patients with T CD4 cells count over 450 cells/mm 3, preferentially whose under HIV replication controlled.